Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab W/WO MK2870 in Resectable Stages II-IIIB(N2) NSCLC for Patients not AchievingpCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy Followed by Surgery

Sponsor:

Merck

Sponsor Study ID:

MK2870-019

CTO #:

103982

NCT Number:

NCT06312137

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

To compare MK-2870 plus pembrolizumab versus pembrolizumab monotherapy with respect to DFS as assessed by BICR. To compare MK-2870 plus pembrolizumab to pembrolizumab monotherapy with respect to OS.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)